These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Lipid-lowering medications: what the new guidelines and data mean to women. Schwartz JB J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105 [No Abstract] [Full Text] [Related]
25. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207 [TBL] [Abstract][Full Text] [Related]
26. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Knoll RW; Ciafone R; Galen M Conn Med; 1993 Sep; 57(9):593-4. PubMed ID: 8252847 [No Abstract] [Full Text] [Related]
27. A Consumer Use Study of Over-The-Counter lovastatin (CUSTOM). Melin JM; Struble WE; Tipping RW; Reynolds JM; Vassil TC; Levy SJ; Petrohoy TM; Midgette P; Hemwall EL; Levine JG; Irvin JD Am J Cardiol; 2004 Nov; 94(10):1243-8. PubMed ID: 15541238 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Landry P; Dimitri E; Tessier S; Légaré N J Clin Psychopharmacol; 2008 Jun; 28(3):348-9. PubMed ID: 18480696 [No Abstract] [Full Text] [Related]
29. [A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia]. Tonstad S; Gørbitz C; Ose L; Malt UF Tidsskr Nor Laegeforen; 1994 Aug; 114(19):2262-4. PubMed ID: 7992293 [TBL] [Abstract][Full Text] [Related]
30. Treatment of lipids. Implications for the general practitioner. Simons LA Aust Fam Physician; 1996 Jul; 25(7):1053-9. PubMed ID: 8768271 [TBL] [Abstract][Full Text] [Related]
31. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia]. Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840 [TBL] [Abstract][Full Text] [Related]
32. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Rubenfire M; Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093 [TBL] [Abstract][Full Text] [Related]
33. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits. Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532 [No Abstract] [Full Text] [Related]
34. Therapeutic use of lovastatin in the treatment of hypercholesterolemia. Illingworth DR Clin Ther; 1994; 16(1):2-26; discussion 1. PubMed ID: 8205598 [TBL] [Abstract][Full Text] [Related]
35. Lovastatin. Feeman WE Am Fam Physician; 1988 Aug; 38(2):65-7. PubMed ID: 3407588 [No Abstract] [Full Text] [Related]
36. [The use of lovastatin in patients with hyperlipemia following heart transplantation treated with cyclosporine]. Anguita M; Alonso-Pulpón L; Arizón JM; Vallés F Med Clin (Barc); 1994 Oct; 103(12):477-8. PubMed ID: 7996901 [No Abstract] [Full Text] [Related]
37. Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. Kandus A; Kovac D; Koselj M; Kveder R; Bren AF Transplant Proc; 1994 Oct; 26(5):2642-3. PubMed ID: 7940824 [No Abstract] [Full Text] [Related]